Artificial Intelligence (AI) has become commonplace to solve routine everyday tasks. Because of the exponential growth in medical imaging data volume and complexity, the workload on radiologists is steadily increasing. We project that the gap between the number of imaging exams and the number of expert radiologist readers required to cover this increase will continue to expand, consequently introducing a demand for AI-based tools that improve the efficiency with which radiologists can comfortably interpret these exams. AI has been shown to improve efficiency in medical-image generation, processing, and interpretation, and a variety of such AI models have been developed across research labs worldwide. However, very few of these, if any, find their way into routine clinical use, a discrepancy that reflects the divide between AI research and successful AI translation. To address the barrier to clinical deployment, we have formed MONAI Consortium, an open-source community which is building standards for AI deployment in healthcare institutions, and developing tools and infrastructure to facilitate their implementation. This report represents several years of weekly discussions and hands-on problem solving experience by groups of industry experts and clinicians in the MONAI Consortium. We identify barriers between AI-model development in research labs and subsequent clinical deployment and propose solutions. Our report provides guidance on processes which take an imaging AI model from development to clinical implementation in a healthcare institution. We discuss various AI integration points in a clinical Radiology workflow. We also present a taxonomy of Radiology AI use-cases. Through this report, we intend to educate the stakeholders in healthcare and AI (AI researchers, radiologists, imaging informaticists, and regulators) about cross-disciplinary challenges and possible solutions.

The prediction of pancreatic ductal adenocarcinoma therapy response is a clinically challenging and important task in this high-mortality tumour entity. The training of neural networks able to tackle this challenge is impeded by a lack of large datasets and the difficult anatomical localisation of the pancreas. Here, we propose a hybrid deep neural network pipeline to predict tumour response to initial chemotherapy which is based on the Response Evaluation Criteria in Solid Tumors (RECIST) score, a standardised method for cancer response evaluation by clinicians as well as tumour markers, and clinical evaluation of the patients. We leverage a combination of representation transfer from segmentation to classification, as well as localisation and representation learning. Our approach yields a remarkably data-efficient method able to predict treatment response with a ROC-AUC of 63.7% using only 477 datasets in total.